Search

Search Constraints

You searched for: Author/Creator Okuma, Yusuke

Search Results

1. 681 Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. (9th November 2020)

2. 681 Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. (9th November 2020)

3. A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin–Pemetrexed Therapy for Non-Small Cell Lung Cancer. (26th September 2014)

4. A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin–Pemetrexed Therapy for Non‐Small Cell Lung Cancer. (26th September 2014)

5. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. Issue 14 (September 2015)

6. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. Issue 14 (September 2015)

7. A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study). (19th May 2020)

9. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. (February 2022)